As a result of the implementation of this program, in the USSR the development of a method for the production of radionuclide ¹²³I suitable for a medical application for the first time was performed at the PNPI synchrocyclotron. The method was based on the production of radionuclide ¹²³Xe by spallation reactions on caesium nuclei at the proton energy of 1 GeV, the extraction of ¹²³Xe on the “on-line” condition and the subsequent disintegration of ¹²³Xe into ¹²³I. Such an approach allowed the production of radionuclide ¹²³I with the radionuclide purity necessary for the medical application even at the unfavourable proton energy as 1 GeV. Using the radionuclide ¹²³I produced at the PNPI synchrocyclotron, methods for the production of radiopharmaceuticals for thyroid diagnosis (sodium [¹²³I]iodide), hepatobiliary system diagnosis ([¹²³I]rose bengal), nuclear cardiology ([¹²³I]Iodopent) were developed. These radiopharmaceuticals passed experimental and clinical tests successfully and they were allowed by the Ministry of Public Health for a wide clinical application. In the course of 1995-2000 implementation of the ¹²³I program had been continued in the Central Research Institute of Roentgenology and Radiology, where a complex for the production of radiopharmaceuticals had been created on a base of the cyclotron MGC-20. The production of radionuclide ¹²³I on the direct reaction ¹²³Te(p,n) ¹²³I up to 500 mCi per run was organized in collaboration with NPO “Girecond”. Using the radionuclide ¹²³I produced at the cyclotron MGC-20, the production of four radiopharmaceuticals were organized, the production of the two radiopharmaceuticals [¹²³I]rose bengal and [¹²³I]Iodopent being established by the Radiochemistry Group.